Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04886726 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Nov 30, 2026 to Nov 30, 2028
    • Study completion date: Nov 30, 2027 to Nov 30, 2028
    v9
  2. Re-verified, no change to tracked fieldsv8
  3. Primary completion date: Nov 30, 2025 to Nov 30, 2026
    • Study completion date: Nov 30, 2025 to Nov 30, 2027
    v7
  4. Primary and study completion dates: Jun 30, 2025 to Nov 30, 2025v6
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 1, 2021 to Dec 23, 2021
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Start date: Nov 1, 2021 to Dec 1, 2021v4
  2. Start date: Jun 19, 2021 to Nov 1, 2021v3
  3. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
So this a Phase I study with primary objective to determine the feasibility and safety of combining post-transplant cyclophosphamide and urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis in stem cell transplant with MMUDs Secondary objectives are to determine the incidence acute and chronic GVHD, progression-free survival , and overall survival
Trial Details
NCT Number NCT04886726
Lead Sponsor Henry Ford Health System
Conditions
(from sponsor)		 Graft Versus Host Disease
Related terms Graft vs Host Disease
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov